Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents.
Aged
Aged, 80 and over
Biomarkers, Tumor
Chromosomes, Human, Pair 14
Chromosomes, Human, Pair 4
Combined Modality Therapy
/ adverse effects
Disease Management
Female
Genetic Predisposition to Disease
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Multiple Myeloma
/ diagnosis
Prognosis
Proportional Hazards Models
Translocation, Genetic
Treatment Outcome
Daratumumab
Multiple myeloma
Novel drugs
Overall response rate
Overall survival
Prognosis
t(4;14) translocation
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
22
06
2020
accepted:
10
09
2020
revised:
04
09
2020
pubmed:
20
9
2020
medline:
22
6
2021
entrez:
19
9
2020
Statut:
ppublish
Résumé
Translocation t(4;14) is an independent prognostic factor for adverse outcome in multiple myeloma (MM). However, reports concerning the therapeutic effects of novel drugs on t(4;14) MM are few. We retrospectively investigated the clinical and prognostic significance of symptomatic MM cases with t(4;14) treated with novel therapies. Ninety-three patients (IgG, 56; IgA, 23; BjP, 14) newly diagnosed with MM were included (median age, 71 years; median observation period, 27.8 months). t(4;14) MM was diagnosed in 17 (IgG, 7; IgA, 9; BjP, 1) patients (18%). An association between t(4;14) and the IgA isotype was confirmed (p = 0.02). Overall survival (OS) at 3 years was lower in the t(4;14) patients than without t(4;14) group (81.2% vs 66.7%, p = 0.04). Multivariate analysis showed that t(4;14) was an independent predictor of OS (hazard ratio [HR], 7.58; 95.0% confidence interval [CI], 1.43-39.9; p = 0.0017). The ORR after autologous blood stem cell transplantation (ASCT) did not differ with or without t(4;14); progression-free survival tended to be prolonged in the group without t(4;14) (p = 0.088). Thus, even in the era of novel drugs, t(4;14) MM still has a poor prognosis, and triplet consolidation therapy should be continued.
Identifiants
pubmed: 32949373
doi: 10.1007/s12185-020-03005-6
pii: 10.1007/s12185-020-03005-6
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
207-213Références
Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64:1546–58.
doi: 10.1158/0008-5472.CAN-03-2876
Gonzalez D, van der Burg M, Garcia-Sanz R, Fenton JA, Langerak AW, Gonzalez M, et al. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood. 2007;110:3112–211.
doi: 10.1182/blood-2007-02-069625
Kumar S, Zhang L, Dispenzieri A, Van Wier S, Katzmann JA, Snyder M, et al. Relationship between elevated immunoglobulin free light chain and presence of IgH translocations in multiple myeloma. Leukemia. 2010;24:1498–505.
doi: 10.1038/leu.2010.128
Kuehl WM, Bergasagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175–87.
doi: 10.1038/nrc746
Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood. 1998;92:3025–34.
doi: 10.1182/blood.V92.9.3025
Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy J Jr. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood. 2003;101:2374–6.
doi: 10.1182/blood-2002-09-2801
Chang H, Stewart AK, Qi XY, Li ZH, Yi QL, Trudel S. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood. 2005;106:353–5.
doi: 10.1182/blood-2005-01-0033
Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Foldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33:2863–9.
doi: 10.1200/JCO.2015.61.2267
Chang H, Sloan S, Li D, Zhuang L, Yi QL, Chen CI, et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol. 2004;125:64–8.
doi: 10.1111/j.1365-2141.2004.04867.x
Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bretsch U, Salwender H, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012;30:2946–55.
doi: 10.1200/JCO.2011.39.6820
Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomized phase 3 study. Lancet. 2010;376:2075–85.
doi: 10.1016/S0140-6736(10)61424-9
Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380:2104–15.
doi: 10.1056/NEJMoa1817249
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–e548548.
doi: 10.1016/S1470-2045(14)70442-5
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.
doi: 10.1038/bmt.2012.244
Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 2002;100:1579–83.
doi: 10.1182/blood-2002-03-0749
Morie AG, Martha QL, Angela D, Greipp PR, Litzow MR, Henderson KJ, et al. Clinical implications of t(11;14)(q13;32), t(4;14)(p16.3;q32), and − 17p13 in myeloma patients treated with high-dose therapy. Blood. 2005;106:2837–40.
Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389:519–27.
doi: 10.1016/S0140-6736(16)31594-X
Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, et al. Treatment with carfilzomib–lenalidomide–dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 2015;1:746–54.
doi: 10.1001/jamaoncol.2015.2010
Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013;31:2540–7.
doi: 10.1200/JCO.2012.46.2119
Yan X, Clemens PL, Puchalski T, Lonial S, Lokhorst H, Moorhees PM, et al. Influence of disease and patient characteristics on daratumumab exposure and clinical outcomes in relapsed or refractory multiple myeloma. Clin Pharmacokinet. 2018;57:529–38.
doi: 10.1007/s40262-017-0598-1
Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715–25.
doi: 10.1038/nri2155
Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319–31.
doi: 10.1056/NEJMoa1607751
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Baksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754–66.
doi: 10.1056/NEJMoa1606038
Mateos MV, Dimopoulous MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. Daratumimab plus bortezomib, melphalan, and predonisone for untreated myeloma. N Engl J Med. 2018;378:518–28.
doi: 10.1056/NEJMoa1714678